Skip to content
Login Register

#IgE

5 public questions tagged with this topic.

Immunological Applications

Omalizumab is used in treatment of:

Severe persistent allergic asthma pathophysiology centers on Th2 polarization with interleukin-4 and interleukin-13 driving class switch recombination from IgM to IgE mediated by AID and germline ε transcription in B cells within bronchial associated lymphoid tissue. Secreted IgE circulates at low concentration 150 ng per ml but binds extremely high affinity FcεRI alpha chain Kd 10^-10 M on mast cells and basophils through Cε3 domain interaction, sensitizing them for months despite short serum half-life two days. Upon re-exposure to perennial aeroallergen such as Dermatophagoides pteronyssinus

Ref: GINA 2023 severe asthma Omalizumab IgE; Holgate Nat Rev Immunol anti-IgE Cε3 blocks FcεRI downregulation.

View Details
Immunological Applications

Omalizumab is used in treatment of:

Omalizumab recombinant humanized IgG1 kappa 149 kDa engineered grafting murine CDRs human framework binding free serum IgE constant region CH3 residues 396-409 overlapping high-affinity Fc epsilon RI alpha and low-affinity Fc epsilon RII CD23 site. Allergic asthma pathogenesis involves IgE 190 kDa produced IL-4 IL-13 driven class switching plasma cells GATA3 Th2 program binding Fc epsilon RI tetrameric alpha beta gamma2 mast cells basophils dendritic cells affinity 10^-10 M persisting weeks surface crosslinking allergen exposure two epitopes bridging IgE triggering Lyn Syk degranulation histam

Ref: FDA Xolair Omalizumab IgE Asthma Label MOA; NEJM Omalizumab Allergic Asthma 2001 Milgrom; Janeway IgE Fc epsilon RI Blockade Downregulation Mechanism.

View Details